Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells

被引:22
|
作者
Teslow, Emily A. [1 ]
Mitrea, Cristina [2 ]
Bao, Bin [1 ]
Mohammad, Ramzi M. [1 ]
Polin, Lisa A. [1 ]
Dyson, Greg [1 ]
Purrington, Kristen S. [1 ]
Bollig-Fischer, Aliccia [1 ]
机构
[1] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[2] Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA
关键词
cancer stem cell-like cells; MBD2; MBD2_v2; obesity; SRSF2; triple-negative breast cancer; BODY-MASS INDEX; DIET-INDUCED OBESITY; POOLED ANALYSIS; ADIPOSE-TISSUE; RISK-FACTORS; INFLAMMATION; FAT; OVERWEIGHT; SURVIVAL; STRESS;
D O I
10.1002/1878-0261.12444
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Obesity is a risk factor for triple-negative breast cancer (TNBC) incidence and poor outcomes, but the underlying molecular biology remains unknown. We previously identified in TNBC cell cultures that expression of epigenetic reader methyl-CpG-binding domain protein 2 (MBD2), specifically the alternative mRNA splicing variant MBD variant 2 (MBD2_v2), is dependent on reactive oxygen species (ROS) and is crucial for maintenance and expansion of cancer stem cell-like cells (CSCs). Because obesity is coupled with inflammation and ROS, we hypothesized that obesity can fuel an increase in MBD2_v2 expression to promote the tumor-initiating CSC phenotype in TNBC cells in vivo. Analysis of TNBC patient datasets revealed associations between high tumor MBD2_v2 expression and high relapse rates and high body mass index (BMI). Stable gene knockdown/overexpression methods were applied to TNBC cell lines to elucidate that MBD2_v2 expression is governed by ROS-dependent expression of serine- and arginine-rich splicing factor 2 (SRSF2). We employed a diet-induced obesity (DIO) mouse model that mimics human obesity to investigate whether obesity causes increased MBD2_v2 expression and increased tumor initiation capacity in inoculated TNBC cell lines. MBD2_v2 and SRSF2 levels were increased in TNBC cell line-derived tumors that formed more frequently in DIO mice relative to tumors in lean control mice. Stable MBD2_v2 overexpression increased the CSC fraction in culture and increased TNBC cell line tumor initiation capacity in vivo. SRSF2 knockdown resulted in decreased MBD2_v2 expression, decreased CSCs in TNBC cell cultures, and hindered tumor formation in vivo. This report describes evidence to support the conclusion that MBD2_v2 expression is induced by obesity and drives TNBC cell tumorigenicity, and thus provides molecular insights into support of the epidemiological evidence that obesity is a risk factor for TNBC. The majority of TNBC patients are obese and rising obesity rates threaten to further increase the burden of obesity-linked cancers, which reinforces the relevance of this report.
引用
收藏
页码:894 / 908
页数:15
相关论文
共 50 条
  • [21] Exploring the interplay between triple-negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies
    Zou, Zhuoling
    Luo, Tinglan
    Wang, Xinyuan
    Wang, Bin
    Li, Qing
    JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (08)
  • [22] Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models
    Sabol, Rachel A.
    Bowles, Annie C.
    Cote, Alex
    Wise, Rachel
    O'Donnell, Benjamen
    Matossian, Margarite D.
    Hossain, Fokhrul M.
    Burks, Hope E.
    Del Valle, Luis
    Miele, Lucio
    Collins-Burow, Bridgette M.
    Burow, Matthew E.
    Bunnell, Bruce A.
    BREAST CANCER RESEARCH, 2019, 21 (1):
  • [23] HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Baez-Navarro, Ximena
    van den Ende, Nadine S.
    Nguyen, Anh H.
    Sinke, Renata
    Westenend, Pieter
    van Brakel, Johannes Bastiaan
    Stobbe, Claudia
    Westerga, Johan
    van Deurzen, Carolien H. M.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [24] HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Ximena Baez-Navarro
    Nadine S. van den Ende
    Anh H. Nguyen
    Renata Sinke
    Pieter Westenend
    Johannes Bastiaan van Brakel
    Claudia Stobbe
    Johan Westerga
    Carolien H. M. van Deurzen
    Breast Cancer Research, 26
  • [25] Zinc-alpha-2-glycoprotein Secreted by Triple-Negative Breast Cancer Promotes Peritumoral Fibrosis
    Verma, Surbhi
    Giagnocavo, Stephanie D.
    Curtin, Meghan C.
    Arumugam, Menusha
    Osburn-Staker, Sandra M.
    Wang, Guoying
    Atkinson, Aaron
    Nix, David A.
    Lum, David H.
    Cox, James E.
    Hilgendorf, Keren I.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (07): : 1655 - 1666
  • [26] ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer
    Fang, Wentong
    Liao, Chengheng
    Shi, Rachel
    Simon, Jeremy M.
    Ptacek, Travis S.
    Zurlo, Giada
    Ye, Youqiong
    Han, Leng
    Fan, Cheng
    Bao, Lei
    Ortiz, Christopher Llynard
    Lin, Hong-Rui
    Manocha, Ujjawal
    Luo, Weibo
    Peng, Yan
    Kim, William Y.
    Yang, Lee-Wei
    Zhang, Qing
    ELIFE, 2021, 10
  • [27] EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
    Fineberg, Susan
    Tian, Xuejun
    Makower, Della
    Harigopal, Malini
    Lo, Yungtai
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2022, 30 (03) : 157 - 164
  • [28] MAT2B expression correlates with poor prognosis in triple-negative breast cancer
    Xu, Jin
    Wu, Di
    Wang, Siliang
    Wang, Zhe
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5501 - 5511
  • [29] Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer
    Gibbs, Lee D.
    Vishwanatha, Jamboor K.
    ONCOTARGET, 2018, 9 (02) : 2697 - 2704
  • [30] Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
    Jeon, Yeonjin
    Jo, Uiree
    Hong, Jongmoo
    Gong, Gyungyub
    Lee, Hee Jin
    BMC CANCER, 2022, 22 (01)